176 related articles for article (PubMed ID: 15968396)
1. Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study.
Langer RD; Pradhan AD; Lewis CE; Manson JE; Rossouw JE; Hendrix SL; LaCroix AZ; Ridker PM
Thromb Haemost; 2005 Jun; 93(6):1108-16. PubMed ID: 15968396
[TBL] [Abstract][Full Text] [Related]
2. Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women.
Pradhan AD; LaCroix AZ; Langer RD; Trevisan M; Lewis CE; Hsia JA; Oberman A; Kotchen JM; Ridker PM
Circulation; 2004 Jul; 110(3):292-300. PubMed ID: 15238458
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study.
Pradhan AD; Manson JE; Rossouw JE; Siscovick DS; Mouton CP; Rifai N; Wallace RB; Jackson RD; Pettinger MB; Ridker PM
JAMA; 2002 Aug; 288(8):980-7. PubMed ID: 12190368
[TBL] [Abstract][Full Text] [Related]
4. Associations of postmenopausal hormone therapy with markers of hemostasis and inflammation and lipid profiles in diabetic and nondiabetic american Indian women: the strong heart study.
Zhang Y; Howard BV; Cowan LD; Welty TK; Schaefer CF; Wild RA; Yeh J; Lee ET
J Womens Health (Larchmt); 2004 Mar; 13(2):155-63. PubMed ID: 15072729
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy.
Rossouw JE; Cushman M; Greenland P; Lloyd-Jones DM; Bray P; Kooperberg C; Pettinger M; Robinson J; Hendrix S; Hsia J
Arch Intern Med; 2008 Nov; 168(20):2245-53. PubMed ID: 19001202
[TBL] [Abstract][Full Text] [Related]
6. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women.
Everett BM; Kurth T; Buring JE; Ridker PM
J Am Coll Cardiol; 2006 Dec; 48(11):2235-42. PubMed ID: 17161253
[TBL] [Abstract][Full Text] [Related]
7. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
Stephenson K; Neuenschwander PF; Kurdowska AK
Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
[TBL] [Abstract][Full Text] [Related]
8. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
[TBL] [Abstract][Full Text] [Related]
9. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines.
Shai I; Rimm EB; Hankinson SE; Curhan G; Manson JE; Rifai N; Stampfer MJ; Ma J
Circulation; 2004 Nov; 110(18):2824-30. PubMed ID: 15492318
[TBL] [Abstract][Full Text] [Related]
10. Associations of von Willebrand factor, fibrin D-dimer and tissue plasminogen activator with incident coronary heart disease: British Women's Heart and Health cohort study.
May M; Lawlor DA; Patel R; Rumley A; Lowe G; Ebrahim S
Eur J Cardiovasc Prev Rehabil; 2007 Oct; 14(5):638-45. PubMed ID: 17925622
[TBL] [Abstract][Full Text] [Related]
11. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
[TBL] [Abstract][Full Text] [Related]
12. Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.
Straczek C; Tafflet M; Barberger-Gateau P; Bertrand M; Dupuy AM; Ducimetière P; Empana JP
Atherosclerosis; 2011 Feb; 214(2):426-31. PubMed ID: 21129746
[TBL] [Abstract][Full Text] [Related]
13. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
Ridker PM; Hennekens CH; Buring JE; Rifai N
N Engl J Med; 2000 Mar; 342(12):836-43. PubMed ID: 10733371
[TBL] [Abstract][Full Text] [Related]
14. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article.
Lakoski SG; Herrington DM
Climacteric; 2005 Dec; 8(4):317-26. PubMed ID: 16390766
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events.
Bray PF; Larson JC; Lacroix AZ; Manson J; Limacher MC; Rossouw JE; Lasser NL; Lawson WE; Stefanick ML; Langer RD; Margolis KL;
Am J Cardiol; 2008 Jun; 101(11):1599-1605. PubMed ID: 18489937
[TBL] [Abstract][Full Text] [Related]
16. Inflammation and hemostasis biomarkers for predicting stroke in postmenopausal women: the Women's Health Initiative Observational Study.
Kaplan RC; McGinn AP; Baird AE; Hendrix SL; Kooperberg C; Lynch J; Rosenbaum DM; Johnson KC; Strickler HD; Wassertheil-Smoller S
J Stroke Cerebrovasc Dis; 2008; 17(6):344-55. PubMed ID: 18984425
[TBL] [Abstract][Full Text] [Related]
17. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS).
Shlipak MG; Chaput LA; Vittinghoff E; Lin F; Bittner V; Knopp RH; Hulley SB;
Am Heart J; 2003 Nov; 146(5):870-5. PubMed ID: 14597937
[TBL] [Abstract][Full Text] [Related]
18. Estrogen plus progestin and the risk of coronary heart disease.
Manson JE; Hsia J; Johnson KC; Rossouw JE; Assaf AR; Lasser NL; Trevisan M; Black HR; Heckbert SR; Detrano R; Strickland OL; Wong ND; Crouse JR; Stein E; Cushman M;
N Engl J Med; 2003 Aug; 349(6):523-34. PubMed ID: 12904517
[TBL] [Abstract][Full Text] [Related]
19. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: the Heart and Estrogen-Progestin Replacement Study (HERS).
Simon JA; Lin F; Vittinghoff E; Bittner V;
Ann Epidemiol; 2006 Feb; 16(2):138-45. PubMed ID: 16039873
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease.
Woodward M; Rumley A; Welsh P; MacMahon S; Lowe G
J Thromb Haemost; 2007 Sep; 5(9):1795-800. PubMed ID: 17723116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
